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Abstract 
The Hyperdense Middle Cerebral Artery Sign (HMCAS) is a specific finding on 
non-enhanced computed tomography (NECT) that correlates with acute ischaemic 
stroke affecting the middle cerebral artery (MCA). It is one of the first 
investigation findings that may be apparent to a clinician and has potential 
implications for management. Given that the HMCAS is seen on the routinely 
performed NECT brain scan and that its presence has significant time-critical 
clinical implications, a clear understanding of the sign is essential. 
A number of investigators have looked at characteristics associated with the sign 
including its reliability, sensitivity, specificity, association with stroke severity, 
comorbid associations, treatment response in patients who present with the sign 
and overall prognosis. The sign appears to be a consistent marker of severe stroke. 
Overall, the patient group presentmg with the sign has been shown to have a poor 
short-term prognosis without thrombolytic therapy and poorer intermediate-long 
term outcome with thrombolytic therapy when compared to patients without the 
sign. 
Chapter 1 presents a literature review on the topic of the HMCAS, detailing and 
summarising the significant findings to date. 
Chapter 2 reports a prospective observational study that has confirmed previous 
results relating to the low sensitivity and high specificity of the sign. It looked 
carefully at comorbid associations with the sign as well as the intermediate-long 
term prognosis of patients not treated with thrombolytic therapy. The results 
vm 
showed that the sign was associated with a more severe initial neurological 
deficit, as well as atrial fibrillation (AF). The 3-6 month outcome of patients in 
this group was poor, with the majority being fully dependent or deceased on 
follow-up. Inter-observer agreement between the two reporting neuroradiologists 
was good, however, the study generated some doubt on the reliability and 
accuracy of HMCAS reporting in general. 
Chapter 3 presents a study that assessed the reliability of HMCAS reporting 
amongst clinicians with varying levels of experience. It also examined how 
accurately and consistently clinicians of similar experience report on the presence 
or absence of an HMCAS when reporting NECT scans. The results showed that if 
a scan was reported not to show an HMCAS, then this was highly likely to be the 
case regardless of the level of experience of the reporting clinician. However, true 
positive scans were far more difficult to report accurately. 
Chapter 4 outlines the key conclusions that can be derived from literature to date 
and the two studies. It further offers recommendations for clinicians dealing with 
HMCAS-positive patients in the setting of acute ischaemic stroke. 
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Chapter One 
LITERATURE REVIEW AND AIMS OF THESIS 
This first chapter examines the existing literature relevant to the background, 
fundamental science and clinical significance of the Hyperdense Middle Cerebral 
Artery Sign. 
The Hyperdense Middle Cerebral Artery Sign (HMCAS) is one of the very early 
suggestive features of pathology, which can be seen on computed tomography 
(CT) scans of the brain in patients presenting with acute ischaemic stroke. In 
recent years, the management of acute stroke has progressed and the ability to 
detect and use these early . signs in clinical decision making is becoming 
increasingly important. Although emerging imaging techniques exist that may 
supercede the use of plain CT in the evaluation of acute stroke, it still remains as 
the primary method in most peripheral hospitals. This thesis outlines, and aims to 
extend upon, the knowledge we have regarding the HMCAS with the goal of 
improving clinical outcomes. 
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1.1 Methods for article selection 
To detect papers reporting the definition, sensitivity, specificity and clinical 
significance of the Hyperdense Middle Cerebral Artery Sign (HMCAS) a primary 
search was conducted using Ovid MEDLINE (1948 - May 2012), EMBASE 
(1980 - . May 2012) and PubMed. Secondary referencing from relevant articles 
was also carried out. Finally a general Google/Google Scholar search with the 
assistance of the "cited by" function was performed. 
A search strategy was developed to identify all publications that directly studied 
epidemiological and clinical parameters associated with the HMCAS, including 
prevalence, sensitivity, specificity, positive and negative predictive values, 
associations with stroke severity and prognosis. The approach used was to 
perform a very broad search and then to apply pre-determined exclusion criteria to 
filter out studies that were not relevant to the topic (Tables l .r-, 1.2 and 1.3). 
The HMCAS has also been r~ferred to as the Dense Middle Cerebral Artery Sign 
(DMCAS) in the literature previously and the search strategy accounted for this. 
Table 1.1. EMBASE search strategy 
Search Terms Articles 
1 middle cerebral artery sign* .mp. 116 
2 middle cerebral artery/ 10567 
3 (hyperdense or hyperdensity or dense or density).mp. 522080 
4 . * sign .mp. 4540833 
5 2 and 3 and 4 211 
6 1 or 5 272 
2 
Table 1.2. Ovid MEDLINE search strategy 
Search Terms Articles 
1 middle cerebral artery sign* .mp. 79 
2 middle cerebral artery/ 2852 
3 (hyperdense or hyperdensity or dense or density).mp. 400900 
4 sign*.mp. 3926049 
5 2 and 3 and 4 46 
6 1 or 5 109 
Table 1.3. Exclusion criteria used as a selection filter 
1 Abstracts not published in English 
2 
Articles that mentioned but did not report any results associated with the 
HMCAS or DMCAS 
3 Non-scientific articles, e.g. Letters to the editor, Opinion articles 
The search strategy associated with tables 1.1 and 1.2 involved detecting articles 
within the time-frame indicated, with all the words *middle-cerebral-artery-sign* 
and the words *hyperdense!hyperdensity or dense/density* within either the title 
and/or the abstract or those articles with the words *middle-cerebral-artery* and 
*hyperdense!hyperdensity or dense/density* and the word *sign* within the title 
and/or abstract. 
This search strategy generated 272 articles from the EMBASE system and 109 
from the Ovid MEDLINE system. The exclusion filter was then applied to these 
results by reviewing each individual abstract. In total 108 relevant articles were 
found. 
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Pub Med was also used to search for relevant articles. An advanced search filter 
was used employing MeSH using the same search terms as above and 116 articles 
were generated, but no new articles were detected. Secondary referencing 
generated an additional 10 articles that were relevant to this chapter. 
A final search using Google/Google Scholar using all permutations and 
combinations of the search terms outlined in tables 1 and 2 did not generate any 
additional articles after searching 20 standard browser pages. 
1.2 Computed Tomography and the definition of the HMCAS 
A CT scan involves the use of X-Rays applied to a patient around a single axis of 
rotation producing multiple two-dimensional images that are then reconstructed 
digitally into a three-dimensional image with computer assistance (Herman , 
2009). 
The use of CT as an imaging technique in the evaluation of patients presenting to 
emergency services with stroke is well established (de Lucas et al., 2008, Vu and 
Lev, 2005, Xavier et al., 2003, Brenner and Hall, 2007). Patients will generally 
receive a plain CT scan of the brain without the addition of contrast dye as a first 
investigation within the emergency department. This type of imaging is also 
referred to as a non-enhanced CT (NECT) scan. A NECT is primarily performed 
to look for evidence of intracranial haemorrhage but it is also used to look for any 
early signs of acute ischemia. 
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The two-dimensional images produced by NECT of the brain can be reconstructed 
as a grey scale three-dimensional image. The resolution is dependent on slice 
thickness. Slices can be of varying thickness, but they are generally Imm thick 
with modem CT reconstructions (Figure 1). 
Figure 1.1. Three single typical NECT axial brain scan slices from three different 
patients - The Canberra Hospital 
The resulting CT scan allows clinicians to view the contents of a patient's skull 
from the base to the apex, looking for any significant abnormality or pathology. 
The grey scale spectrum from black through to white is a representation of the 
degree of absorption of X-Rays which occurs during the scanning. As a general 
rule, the denser the material the more X-Rays are absorbed and the brighter or 
whiter the image will appear on the resultant digital slices. 
The radiological density can be objectively measured using Hounsfield Units 
(HU). Computer programs have been designed to specifically analyse NECT 
scans in this way. The HU scale is a linear transformation developed to quantify 
the radiological density of human tissues relative to water (zero HU) (Herman, 
2009). 
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The cerebrospinal fluid (CSF) within the ventricles of the brain usually looks 
black (15 HU), while brain parenchyma appears as varying shades of grey (white 
matter 20-30 HU, grey matter 37-45 HU). Blood vessels are somewhat whiter due 
to their haemoglobin ( and therefore iron) content (,..., 40 HU) and bone is seen as 
white due to its high-density calcium-based matrix ,..., 1000 HU) (Herman, 2009) 
(Figure 1.2). 
Blood vessels; in this 
case the middle 
cerebral artery (MCA) 
""Cerebral parenchyma 
any skull 
Figure 1.2. Typical NECT brain scan slice demonstrating the 
various radiological densities of intracranial structures 
The Canberra Hospital 
In 1983 Gacs et al. noted an unusually dense middle cerebral artery (MCA) on the 
CT brain scan of a patient suffering acute ischemic stroke whose symptoms were 
consistent with pathology in this territory. A cerebral angiogram ( a technique 
employing the use of radio-opaque dye to allow accurate imaging of the 
cerebrovascular system) was performed to investigate this further and 
demonstrated an occlusion of the MCA that correlated directly with the increased 
density seen on the NECT. Three subsequent patients with the same clinical 
scenario and NECT findings were investigated in the same way and all proved to 
have occlusions on their angiogram that correlated with the "hyperdensity " seen 
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on the NECT (Gacs et al., 1983). This was the first formal description of the 
HMCAS, (though it was initially referred to as the DMCAS before the addition of 
the prefix "hyper" in the late 1980s by Schuierer and colleagues (Schuierer and 
Huk, 1988). 
In summary, the HMCAS is defined as an appearance of increased attenuation or 
radiological density over and above that which would be expected of the normal 
proximal MCA on NECT (Figure 1.3). The HMCAS is one of the only 
radiological signs that may be seen on NECT within the first few hours of 
ischaemic stroke and is therefore important to identify (Mullins, 2005). 
Figure 1.3. An example of a typical right-sided HMCAS 
The Canberra Hospital 
The definition of this sign is subjective and, because specialist radiologists 
generally report it, there has been significant disagreement on what actually 
constitutes an HMCAS. 
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The ability to detect a sign reliably and reproducibly is crucial to the practice of 
clinical medicine. The fact that the HMCAS is not usually measured objectively, 
but rather commented on as present or absent based on observation and 
experience, is an important issue. 
To improve the accuracy of reporting the HMCAS for the purposes of research, 
most investigators utilise two neuroradiologists and only accept the sign as 
present if both agree (Samford et al., 2002, Mattle et al., 2008, Abul-Kasim et al., 
2009). 
A number of studies have been setup to evaluate the level of agreement between 
observers as well as to generate objective technical definitions of the HMCAS 
(Tomsick et al., 1990, von Kummer et al., 1994, Koo et al., 2000, Abul-Kasim et 
al., 2009). These studies have used the Kappa statistic to evaluate inter-observer 
agreement. This method is a simple technique that calculates the percentage of 
agreement between observers and then adjusts for the agreement that would 
otherwise have occurred by chance (Landis and Koch, 1977, Viera and Garrett, 
2005). It is considered by many to be a conservative estimate of agreement and 
follows a qualitative scale as shown in figure 1.4. 
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Interpretation of Kappa 
Poor Slight Fair Moderate Substantial Almost perfect 
Kappa O .0 .20 .40 .60 .80 1 .0 
Kappa 
<0 
0.01-0.20 
0.21- 0.40 
0.41-0.60 
0.61-0 .80 
0.81-0.99 
Agreement 
Less than chance agreement 
Slight agreement 
Fair agreement 
Moderate agreement 
Substantial agreement 
Almost perfect agreement 
Figure 1.4. Interpretation of the Kappa statistic 
Viera AJ , Garrett JM. Understanding interobserver agreement: The kappa 
statistic. Family Medicine. 2005;37:360-363 
Published Kappa values range between 0.38 and 0.69 for blinded reporting and 
0.53 and 0.86 for un-blinded reporting. In other words, when a radiologist is 
provided with clinical information about the patient whose NECT they are 
reporting, the level of agreement on the presence or abse~~e of the HMCAS 
improves. It is important to note that the various studies were conducted both 
before and after the advent of. CT using Imm axial reconstructions. The earlier 
studies may therefore have been less sensitive and so generated reduced detection 
rates (Eung et al., 2005). 
When HMCAS-positive scans were analysed using HU it was found that all 
radiologists agreed on the presence of an HMCAS in the following situations: 
• MCAartenuation ~ 46 HU and MCAattenuation ratio > 1.2 using oval regions of 
interest (ROis) or 
• MCAattenuation ~ 50 HU and MCAattenuation ratio of> 1.4 using pixel sized ROis 
( Abul-Kasim et al., 2009). 
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This means that when the radiological MCAs are digitally highlighted using an 
oval region sampling technique, an HMCAS is always agreed as being present if 
the attenuation is greater than or equal to 46 HU and it is at has a radiological 
density of at least 1.2 times that of the contralateral side. Furthermore , if a pixel-
sampling ROI technique is used, the values for universal agreement on the 
HMCAS rise to 50 HU and 1.4 respectively. 
Given the subjective nature of reporting and the fact that the objective criteria 
listed above are not used in routine clinical medicine due to their impracticality , 
the ability to detect the sign is heavily reliant on the capacity of the reporter. It is 
likely that the level of experience of the reporter is an important determining 
factor in the accuracy of HMCAS detection. Given the importance of detecting 
the HMCAS in an acute setting, it would be useful to know how reliably it is 
reported amongst medical staff of varying levels of experi~nce. There are no 
studies to date that look at this and further evaluation is required. 
Figure 1.5. An example of an HMCAS using HU measurements and oval ROls. The 
image on the right shows a very typical right-sided HMCAS with an attenuation of 55 
HU as compared to the opposite MCA on the left hand image measuring on 33 HU with 
a ratio of 55/33 = 1 .67 
The Canberra Hospital 
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1.3 Prevalence, sensitivity and specificity of the HMCAS 
As outlined earlier, the HMCAS was first described in the setting of ischaemic 
stroke and, in particular, was correlated with MCA occlusion on cerebral 
angiography. Subsequent studies have shown that the HMCAS is most obvious 
during the first 6 hours of severe acute ischemic strokes (Giroud et al., 1990, 
Pressman et al., 1987). 
Several studies have looked at the prevalence of the HMCAS within the stroke 
population as well as how sensitive and specific the sign is for ischemic stroke. 
The results of these studies consistently report that the prevalence of the HMCAS 
within the MCA stroke population at between 25% and 40% when the NECT is 
performed within 6 hours of stroke onset (Tomsick et al., 1989, Leys et al., 1992, 
Fiorelli et al., 2000, Hengirmen et al., 2002, B astianello et al . ,--1991). A key point 
associated with this result is that very few HMCAS have been reported on the 
NECT scans of patients who did not suffer MCA territory strokes. To date, no 
study has looked carefully at the prevalence of the sign outside the stroke 
population. 
In one of the above studies the investigators re-scanned patients at one week and 
again at three months after their initial stroke. Two-thirds of those patients with an 
HMCAS on their initial scan no longer demonstrated an HMCAS after one week 
and all were HMCAS-negative at three months. A sample of these patients 
underwent cerebral angiograms and the results showed that the disappearance of 
the HMCAS corresponded with recanalisation of the blood vessel (B astianello et 
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al., 1991). In other words, cerebral angiography results in HMCAS-positive 
patients correlate with both the presence and the disappearance of the sign. 
Since very few studies have assessed the prevalence of the HMCAS outside the 
stroke population, the general sensitivity and specificity cannot be commented on. 
Two large prospective studies have carefully evaluated the specificity of the 
HMCAS within the stroke population. One reported a specificity of 100% and the 
other 95% for ischaemic stroke within the MCA territory (Leys et al., 1992, 
Fiorelli et al., 2000). The larger of the two studies also calculated the sensitivity of 
the sign to be 30%. 
In one secondary analysis of a database of NECT scans, 13 scans were found to be 
HMCAS-positive in the absence of stroke (Rauch et al., 1993). The authors 
reported that these patients had a statistically higher haematocrit and also a higher 
prevalence of hypertension and diabetes mellitus than patients without an 
HMCAS. This study is often used as evidence for a low false-positive rate 
associated with the HMCAS. However, very few subsequent investigators have 
found similar results, most finding no false positives at all (Jha and Kothari, 2009, 
Mullins, 2005). 
Case reports have described patients who have presented with an HMCAS in the 
context of head and neck trauma. However, the underlying pathology was found 
to be intravascular occlusion caused by the distal migration of intraluminal carotid 
artery thrombus ( caused by trauma) (Shuaib and Crotch-Harvey, 1995). There 
have been a small number of other reports of the HMCAS appearing outside the 
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context of stroke. These cases involved herpes simplex encephalitis and middle 
cerebral artery dissection (Maramattom and Wijdicks, 2004, Y akushiji et al., 
2006). 
In summary, the HMCAS appears to be present in approximately one quarter to 
one third of all NECT brain scans of patients suffering an ischaemic stroke within 
the MCA territory. The sign is highly predictive of an MCA stroke and presence 
of the sign is associated with a very high positive predictive value. Conversely, 
the HMCAS has a low sensitivity and so its absence does not exclude stroke. 
Further formal investigations into the epidemiological significance of the 
HMCAS are required to determine its prevalence, sensitivity and specificity more 
accurately. 
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1.4 Association between the HMCAS initial stroke severity and 
other clinical features 
The initial neurological deficit of stroke patients can be measured in a number of 
ways. Two common scales used to quantify the severity of a stroke objectively at 
the time of presentation are the Scandinavian stroke scale (SSS) and the National 
Institutes of Health Stroke Scale (NIHSS) (Kasner et al., 1999, Scandinavian 
Stroke Study Group, 1985). These scales function similarly in that they provide a 
scoring system to grade stroke severity based on neurological examination. The 
SSS score ranges from 2 in a maximally impaired patient to 58 in a nom1al 
person. The NIHSS is scored in reverse, such that a patient with a completely 
normal neurological exam and normal mental status will have a score of O, while 
the maximum recordable NIHSS score is 42. 
As an example, a typical patient with a left MCA occlusion and NIHSS score of 
10 might exhibit minimal drowsiness, minor facial paresis, no resistance to 
gravity with a right arm or leg, partial sensory loss, partial neglect, and mild 
dysarthria. This deficit would correlate to an SSS score of 40 (Tomsick et al., 
1996). 
The presence of the HMCAS in acute stroke has been consistently shown to be 
associated with a more severe initial deficit. A number of small studies and two 
large retrospective studies have demonstrated this clearly. When using the NIHSS 
scoring system, stroke patients with an HMCAS on their NECT had a median 
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score of approximately 20, with none lower than 10, compared to, a median score 
of 10 in those without an HMCAS (Tomsick et al., 1996, Scott et al., 1999). 
Those investigators using the SSS to measure initial deficit have reported similar 
findings with HMCAS-positive patients. The large secondary analysis of the 
European Cooperative Acute Stroke Study I (ECASS I) showed that HMCAS-
positive patients had a median SSS of 23 .4 versus 29 .4 in those without the sign 
(Manelfe et al., 1999). This study also showed that patients with the sign were 
more likely to show other early changes on their NECT associated with larger 
strokes, such as oedema and secondary haemorrhage. 
Leys et al performed the first comprehensive study looking at clinical parameters 
associated with the HMCAS (Leys et al., 1992). Demographic and clinical data 
-
were prospectively recorded for 272 patients including age, cerebral atrophy, 
leukoaraiosis, sex, history of hypertension, diabetes mellitus, cardiovascular 
diseases, elevated blood cholesterol, elevated blood triglycerides, coagulopathy, 
evidence of cerebral embolism from heart, embolism from artery and small-vessel 
disease. After analysis, the authors did not identify any correlation between the 
presence of an HMCAS and the clinical factors listed above. The authors do 
however agree that embolism is the most likely mechanism for large MCA 
occlusion and the presence of an HMCAS based on previous autopsy studies. 
A smaller retrospective study showed that atrial fibrillation (AF), increasing age 
and diabetes were positively correlated with the presence of an HMCAS in 
ischaemic stroke patients (Zorzon et al., 1993). Berge et al further showed that AF 
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was far more common within the group of patients suffering a large stroke and 
that this association was even stronger within the HMCAS-positive group (Berge 
et al., 2001). 
It is known that AF is more common within the population of patients suffering 
large ischaemic stroke (Dulli et al., 2003, Kimura et al., 2005). A recent study 
looked at the NECT scans of 50 consecutive cases of acute MCA ischaemic 
stroke. The occlusions were retrieved by mechanical thrombectomy and 
underwent histopathologic analysis, including automated quantitative and 
qualitative rating of the proportion of composed red blood cells, white blood cells, 
and fibrin on microscopy of sectioned thrombi. The results showed that the 
HMCAS was more commonly seen with red blood cell-dominant and mixed clots 
than with fibrin-dominant clots, with the mean percent red blood cell composition 
being significantly higher (47% versus 22%, p = 0.016). These results provide 
pathological evidence that HMCAS strokes are more likely to originate from 
upstream larger thromboemboli such as the clots that form in the heart in AF 
(Liebeskind et al., 2011, Minnerup and Kleinschnitz, 2011). 
In summary, it appears that the HMCAS is associated with a more severe initial 
neurological deficit and the presence of AF. However, very little prospective work 
has been conducted to identify the co morbid associations of the sign. 
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1.5 Prognostic implications of the HMCAS with and without 
thrombolysis 
The prognostic implications of the HMCAS have been studied in various settings. 
Ischaemic stroke pat_ients have been followed up using different timing protocols 
and different levels of intervention. This section will summarise the findings to 
date. 
1.5.1 Prognostic implications of the HMCAS primarily without 
thrombolysis 
The first study to look at prognostic implications involved 50 patients who were 
prospectively recruited at the time of ischaemic stroke (Launes and Ketonen, 
1987). Thirteen of them demon~trated an HMCAS on their NECT and 37 did not. 
Clinical outcome was ascertained from the notes and graded at the time of 
discharge from the hospital, the precise time of which was not defined. The 
grading scale used was as follows: 
(1) Fully independent in activities of daily living (ADL) 
(2) Requires minor assistance in ADL 
(3) Requires constant assistance in ADL 
(4) Totally dependent, requires hospitalisation 
(5) Dead 
17 
The results of this study revealed that 10/13 patients with the HMCAS died during 
their hospital stay as compared to 2/37 within the control group (p < 0.01). This 
was the first clear report that the sign implied a poor prognosis. 
In 1991 a retrospective examination of the 90 patients consecutively recruited in 
the Italian acute stroke study was carried out. Fourteen of their patients 
demonstrated an HMCAS and all were followed up at 21 days post stroke and 
evaluated using the modified Rankin scale (mRS). The mRS is detailed in table 
1.4 and has been validated a number of times as a tool for measuring functional 
outcome post stroke (Bonita and Beaglehole, 1988). 
Table 1.4. Modified Rankin scale 
Score Description 
0 No symptoms at all 
No significant disability despite symptoms; able to carry out all usual duties and activities 
2 Slight disability; unable to carry out all previous activities , but able to look after own affairs 
without assistance 
3 Moderate disability; requiring some help , but able to walk without assistance 
4 Moderately severe disability; unable to walk without assistance and unable to attend to own bodily 
needs without assistance 
5 Severe disability; bedridden, incontinent and requiring constant nursing care and attention 
6 Dead 
This particular study defined a score of 1-3 as a good outcome and 4-6 as a bad 
outcome. Only 29% of patients with an HMCAS were graded with a good 
outcome at 21 days (p = 0 .03) as compared to 63 % without the sign (Ricci et al., 
1991). 
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Subsequently, a number of similar studies were conducted confirming that the 
HMCAS is associated with greater short-intermediate term disability or death 
(Leys et al., 1992, Moulin et al., 1996, Berge et al., 2001, Schuierer and Huk, 
1988, Samford et al., 2002). 
Table 1.5 summarises the larger studies. 
Table 1.5. Studies evaluating the prognostic implications of the HMCAS without 
interventional thrombolysis 
Author/Year Design Intervention Outcome Follow-up Result 
Measure time 
(Launes and Prospective - Non-mRS At HMCAS associated with poor 
Ketonen , 1987) discharge outcome 
(not 
defined) 
(Ricci et al., Retrospective - mRS 21 days HMCAS associated with poor 
1991) outcome 
29% of HMCAS +ve mRS 1-3 Vs 
63% HMCAS -ve mRS 1-3 
(Leys et al., Prospective 10 days Non-mRS 14-16 days HMCAS not an independent 
1992) Nimodipine/ predictor of poor outcome after 
Heparin analysis 
(Moulin et al., Prospective - mRS At HMCAS associated with poor 
1996) discharge outcome 
(not 17 /22 HMCAS +ve patients had 
defined) mRS>4 
(Berge et al., Secondary Heparin Vs mRS/IST 14 days HMCAS was an independent 
2001) Analysis Aspirin and 3 predictor of parenchymal 
months haemorrhage on NECT and of 
death, but not other levels of 
disability after regression analysis 
(Samford et al. , Retrospective At HMCAS associated with poor 
2002) discharge,..., outcome 
25 days Note: Proximal HMCAS worse 
than distal HMCAS 
A few key comments on the above reports are as follows: 
Although the study by Leys et al was the largest prospective study it was the only 
study not to demonstrate that an HMCAS was associated with poorer short-term 
outcome after multiple linear regression analysis accounting for patient 
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comorbidities. 
Data from the large multi-centre double-blind randomised controlled trial 
assessing Aspirin versus Heparin in acute stroke (the International Stroke Trial) 
were subjected to a secondary analysis and published (Berge et al., 2001). The 
results showed that patients who had an HMCAS on their NECT were more likely 
to have other adverse features on their brain scans as well as an increased risk of 
death both at 14 days and 3 months post stroke. These were the only two 
outcomes that had an independent positive correlation with the presence an 
HMCAS after controlling for patient comorbidities. 
A more recent study by Somford et al reviewed the records of 352 patients who 
suffered acute ischaemic stroke. In this study neuroradiologists stratified the 
HMCAS as either proximal or distal (Somford et al., 2002). These two regions 
refer to the Ml segment and the M2 segment of the MCA, resp-ectively. Examples 
of these two signs are displayed in figure 1.6. 
a. b. 
Figure 1.6. Transverse CT scans show (a) proximal and (b) distal HMCAS ("dot 
sign") 
Samford OM, Nederkoorn PJ, Rutgers DR, Kappelle LJ , Mali WPTM , van der Grand J. Proximal and 
distal hyperattenuating middle cerebral artery signs at ct: Different prognostic implications . Radiology. 
2002;223 :667-671 
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The results of this study showed that a proximal HMCAS, which correlates with a 
greater filling defect on formal cerebral angiography, is associated with poorer 
outcome at time of hospital discharge compared to a distal HMCAS. 
In summary, the HMCAS is associated with poorer short term outcome. However, 
no intermediate to long term prospective studies have been carried out to evaluate 
patient ouctcome in the absence of thrombolyitic therapy. 
1.5 .2 Prognostic implications of the HMCAS with thrombolysis 
1.5.2.1 Intravenous thrombolysis and the HMCAS 
The majority of strokes are due to blockage of an artery in the brain by a blood 
clot, i.e an ischaemic stroke. Prompt treatment with thrombolytic drugs (whose 
mechanism of action is to dissolve clot) significantly improves outcome in 
appropriately selected patients. Thrombolytic drugs can, however, also cause 
serious bleeding in the brain that can be fatal. One drug, recombinant tissue 
plasminogen activator (rtP A), is licensed for use in highly-selected patients out to 
4 .5 hours post stroke (Wardlaw Joanna et al., 2009, Shobha et al., 2011 b). 
The first study examining how patients with an HMCAS respond to thrombolysis 
looked prospectively at 50 ischaemic stroke patients. Twenty-five of these 
patients exhibited an HMCAS on their initial NECT and the most significant 
result was that the sign carried a 32% positive predictive value for fatal clinical 
outcome despite thrombolysis (von Kummer et al. , 1994). In other words , the sign 
carried a 32% mortality rate during the hospital admission in this cohort of 
patients. 
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Numerous subsequent studies have been carried out to assess the associations 
between the HMCAS, intravenous thrombolysis and outcome (Tomsick et al., 
1996, Manelfe et al., 1999, Mendizabal et al., 2001, Qureshi et al., 2006, Tartaglia 
et al., 2008, Aries et al., 2009, Abul-Kasim et al., 2010). A number of the larger 
studies published to date are summarised in table 1.6. 
Table 1.6. Studies evaluating the prognostic implications of the HMCAS with intravenous 
thrombolysis 
Author/Year I Design I Outcome 
Measure 
(von Kummer I Prospective I Non-rnRS 
et al., 1994) 
(Tomsick et I Retrospective I NIHSS 
al., 1996) score 
(Manelfe et 
al., 1999) 
Secondary 
Analysis of 
double blind 
randomised 
RCT 
(thrombolysis 
vs placebo) 
(Mendizabal I Retrospective 
et al., 2001) 
(Qureshi et al. , I Prospective 
2006) 
(Tartaglia et 
al., 2008) 
Retrospective 
rnRS 
rnRS 
rnRS/ 
NIHSS 
score 
mRS 
Follow-up 
time 
Observed 
during 
hospital 
admission 
3 months 
3 months 
Result 
HMCAS carried an increased risk of death 
when compared to patients who did not 
exhibit the sign (32% PPV) 
The median NIHS S score of the 18 
HMCAS-positive patients was 9 compared 
with 5 in the 37 HMCAS-negative patients. 
Only 1 of the 18 HMCAS-positive patients 
was completely improved at three months 
compared with 17 of the 37 HMCAS 
negative patients. 
Both HMCAS-positive and negative 
patients as group demonstrated significant 
improvement in symptoms after 
thrombolysis. 
HMCAS associated with poor functional 
outcome, rnRS 3-6 on univariate analysis. 
However, the association was no longer 
significant in a logistic model accounting 
for demographic, other initial NECT 
changes and treatment. 
Patients with an HMCAS as a group 
performed better with thromboylysis, than 
those who did not receive treatment at all. 
3 months I No prognostic trend established with 
HMCAS, i.e.. no significant different 
between groups was found 
3 months I HMCAS was associated with lower rates of 
rnRS 0-1 or NIHSS Score 0-1 at 3 months , 
however overall improvement was 
significant 
24 hrs post 
thrombolysis 
and 3 months 
The mean NIHSS score 24 hours after 
treatment was slightly higher in the 
HMCAS. In a multiple logistic regression 
analysis, the only independent predictor of 
poor outcome (rnRS 3-6) was pre-treatment 
NIHSS score. Overall patients with 
HMCAS were not worse off at 3 months. 
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(Kharitonova Retrospective mRS 3 months HMCAS-positive patents had reduced levels 
et al., 2009a) of independence (mRS > 2) and higher 
mortality rates. 
HMCAS was not an independent predictor 
of intracranial haemorrhage and 
recommended HMCAS group should still 
receive thrombolysis , as the overall benefit 
was not discounted . 
Most of the above studies show that in patients who received intravenous 
thrombolysis the HMCAS is associated with a poorer short-intermediate term 
outcome when compared to those without the sign. Furthermore, there appears to 
be a particular subgroup of HMCAS-positive patients who do very poorly. Having 
said this, the group as a whole still benefited from thrombolytic therapy. 
Two retrospective studies evaluated the rate of intracerebral haemorrhage amongst 
stroke patients who underwent intravenous thrombolysis, comparing HMCAS-
positive and negative patients. Both studies, the largest of which comprised over 
ten thousand patients, did not show any significant difference between groups 
(Aries et al., 2009, Kharitonova ,et al., 2009a). 
A key point raised by many of the above studies that used multiple regression 
analysis to control for comorbidities, other NECT findings, and initial stroke 
severity, is that the HMCAS may simply be a surrogate marker for severe stroke 
and, although it does correlate with poorer outcome, it is often not independently 
associated with it. 
In summary, patients who present with an HMCAS and receive intravenous 
thrombolysis appear to benefit less as a group than those who do not present with 
the sign. Overall, however, they benefit more than those who do not receive 
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intravenous thrombolysis at all. Importantly, HMCAS-positive patients do not 
appear to be complicated by haemorrhage any more often than patients without 
the sign when looking at groups of patients with strokes of comparable severity. 
More research needs to be conducted to evaluate why certain subgroups of the 
HMCAS-positive population perform more poorly than others when treated with 
thrombolysis. One method of approaching this would be to look at previous major 
and current thrombolysis trials and assess for these relationships with the HMCAS 
specifically. 
1.5 .2.2 Studies assessing recanalisation with intravenous thrombolysis in 
HMCAS patients 
--
A number of studies have looked at follow-up NECT scans to evaluate whether or 
not disappearance of the HMCAS after thrombolysis is a surrogate marker for 
recanalisation. These studies have also looked at functional outcome. 
Disappearance of the HMCAS does appear to correlate with recanalisation and 
improved outcome. However, the approach applied by different investigators has 
varied. A brief summary of the results from the larger reports is outlined below. 
One such study sought to evaluate arterial recanalisation as measured by changes 
in the presence of HMCAS on initial and 24-hour NECT scans in patients treated 
with intravenous thrombolysis or placebo, and to compare this to patient outcome 
(Nichols et al., 2008). A baseline HMCAS was seen in 79 of 604 eligible patients 
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(13%). Of these 79 patients, 14 of 37 (38%) treated with thrombolysis had 
resolution of HMCAS at 24 hours compared with 7 of 42 (17%) treated with 
placebo (p = 0.03). Infarct volumes as measured on NECT at 24 hours were 
significantly smaller in treated patients who had received thrombolysis and had 
resolution of the sign when compared with those who had persistence of the sign 
(p = 0 .004). Functional outcomes were not significantly correlated with resolution 
of the HMCAS in either treatment group. 
Overall, recanalisation appeared to occur more often in the HMCAS group 
exposed to thrombolytic therapy. However, this did not correlate with improved 
outcome. 
Kharitonova et al studied 1905 ischaemic stroke patients with an HMCAS on 
initial NECT from the Safe Implementation of Treatment in Stroke-International 
Stroke Thrombolysis Register (Kharitonova et al., 2009b). HMCAS 
disappearance was treated as a surrogate marker for MCA recanalisation. Follow-
up NECT scans at 22-36 hours post thrombolysis were examined and the 3-month 
mRS was assessed, independence being defined as a mRS score of 0-2. 
The HMCAS disappeared in 831 cases, persisted in 788, and was indeterminate in 
122. The remainder did not receive a follow-up NECT. Patients whose HMCAS 
disappeared were younger in age and had milder strokes as determined by their 
admission NIHSS scores. They were more likely to be independent at 3 months 
(42% vs 19%) and less likely to be dead (15% vs 30%) than patients with 
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persistent HMCAS. In multivariate analysis, HMCAS disappearance 
independently predicted functional independence and survival. 
This very large and comprehensive analysis suggested that patients whose 
HMCAS disappears behave in a similar fashion after thrombolysis to patients with 
similar strokes without the sign. Conversely, approximately half of the patients 
had a persistent HMCAS on follow up NECT at 22-36 hours, probably reflecting 
failure to recanalise. It is this group of patients that appears to generate the poorer 
thrombolysis results in HMCAS-positive patients as a whole. 
A similarly designed smaller study with data collected prospectively from a single 
tertiary referral center generated results consistent with the above analysis 
(Paliwal et al., 2011). Again, the most concerning group comprised those who had 
--
a persistent HMCAS on follow up NECT as they received the smallest benefit 
from thrombolysis. The one additional piece of insight provided by these results 
was that patients who demonstrated early parenchymal changes in addition to 
their HMCAS on their initial NECT were more likely to have persistence of the 
HMCAS. This relationship requires further evaluation. 
At about this time, multiple concurrent studies were being conducted that were 
looking at whether the use of modem CT scanners could more accurately evaluate 
the volume of thrombus that an HMCAS represented and hence whether the size 
of the HMCAS correlated to clot burden and an inability to recanalise (Riedel et 
al., 2010b, Riedel et al., 2010a, Kim et al., 2008). Based on angiographic and 
clinical follow-up studies it was confirmed that thin slice NECT scans could 
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predict underlying thrombus volume and that patients with longer HMCASs did 
have poorer outcomes in terms of recanalisation and disability. 
More specifically, the first study to look at this phenomenon in detail was 
retrospectively conducted and analysed admission NECT images of 2.5mm slice 
width of 127 patients. 
The length of the HMCAS was measured in all patients who demonstrated the 
sign and patients were assessed for recanalisation within the first 48 hours after 
thrombolytic therapy either by transcranial ultrasound, magnetic resonance 
imaging or CT angiography. 
The results showed that in 12 patients (9%) a HMCAS was not detected and that 
--
in none of these patients vascular occlusion was found after treatment. Patients 
with an HMCAS of 4mm or less resulted in a recanalisation rate of 61 % after 
treatment and a thrombus length of 6mm resulted in recanalisation in 12 % of 
patients. Finally, a HMCAS length of more than 8mm saw less than 1 % of 
patients successfully recanalise in that group. 
This study provided the basis for a quantitative framework when assessing the 
potential benefit of intravenous thrombolysis in patients presenting with an 
ischaemic stroke and an HMCAS. Importantly, the measurement is based on 
NECT scans alone. 
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In addition to the above work, Shohba et al. proposed that recanalisation should 
occur more often in patients with a smaller HMCAS (Shobha et al., 2011a). They 
sought to correlate HMCAS length with HMCAS volume and to determine what 
threshold of HMCAS length would disappear when exposed to intravenous 
thrombolytic therapy. A cohort of patients with Ml occlusion on CT angiography 
was chosen for the study and the patients' data were collected retrospectively. The 
length of the HMCAS was measured on the initial plain NECT using specialised 
software. Similar measurements were performed on follow-up NECT brain scans 
performed within 1- 2 days of thrombolysis. One hundred and four patients with 
acute ischaemic stroke were found to have an HMCAS on NECT with Ml MCA 
occlusion confirmed by CT angiography. The mean baseline volume of the 
hyperdense Ml was 0.353 ± 0.224 ml and the mean baseline length was 1.66 ± 
0.83 cm. There was a significant correlation between length and volume. Of the 
104 patients, 41 received intravenous thrombolysis. The likelihood of 
disappearance of the HMCAS varied depending on the baseline HMCAS length: 
• 
• 
• 
Short length HMCAS (< 1cm) disappeared in 6/7 (85.7 %) 
Medium length HMCAS (1-2 cm) disappeared in 9/24 (37. 5%) 
No cases of long length HMCAS (> 2cm) cm disappeared (0/10) 
(p=0.05)(Shobha et al., 201 la) 
I~ summary, the disappearance of an HMCAS on early follow-up NECT brain 
scan does appear to correlate with recanalisation and improved outcome. Having 
said this, a significant portion of patients who present with an HMCAS have a 
persistent HMCAS and do not improve with intravenous thrombolysis. The 
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volume of the underlying clot may account for this difference. The length of the 
HMCAS on NECT may assist in identifying at-risk patients. Further evaluation of 
subgroups within the HMCAS-positive population is required. 
1.5.2.3 Intravenous versus intra-arterial thrombolysis in HMCAS patients 
Conventional (intravenous) thrombolysis is given through a peripheral vem. 
However, intra-arterial thrombolysis, which is currently undergoing extensive 
trials, involves the administration of thrombolytic agents through a peripherally-
inserted and centrally-deployed catheter. 
Only two studies have looked at the benefit of intra-arterial therapy within the 
HMCAS-positive subgroup and a summary of the results are outlined below. 
A study published in 2004 evaluated 83 consecutive ischaemic stroke patients (66 
treated with intravenous therapy, 17 with intra-arterial therapy) (Agarwal et al. , 
2004). In this study, initial and discharge NIHSS scores and 90-day follow up 
mRS were recorded for each patient. A favorable outcome was noted with intra-
arterial thrombolysis irrespective of the presence (p = 0.001) or absence (p = 0.01) 
of the HCMAS on initial NECT. A less favorable outcome in terms of discharge 
NIHSS score was noted in HMCAS-positive patients treated with intravenous 
therapy when compared to those without the sign (p < 0.001). 
The trends outlined above persisted at 90-day follow up when using the mRS in 
patients who received intra-arterial thrombolysis. Of the patients who received 
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intravenous thrombolysis, the majority of patients demonstrated significant 
improvement. However, the HMCAS-positive group as a whole had a somewhat 
worse outcome. 
The data from two stroke units were compared in a more recent study. One stroke 
unit performed intra-arterial thrombolysis and the other performed intravenous 
thrombolysis (Mattle et al., 2008). Outcome was measured at 3 months using the 
mRS, which was dichotomized into favorable (mRS O to 2) and unfavorable (mRS 
3 to 6). One hundred and twelve patients exhibited an HMCAS (55 treated with 
intra-arterial thrombolysis and 57 treated with intravenous thrombolysis). After 
multiple regression analysis, intra-arterial thrombolysis was associated with a 
more favorable outcome than intravenous therapy (p = 0.003). However, both 
groups had similar mortality rates. 
Although intra-arterial thrombolysis has not yet been proven to be more 
advantageous than intravenous thrombolysis in the ischaemic stroke population as 
a whole, it may provide additional benefit to carefully selected patients who 
present with an HMCAS. 
1.5.2.4 Other suggested approaches to stroke patients with an HMCAS 
More recently, a novel technique has been developed to assist in the treatment of 
acute ischaemic stroke with intravenous thrombolysis. This strategy is referred to 
as ultrasound-enhanced thrombolysis or sonothrombolysis , early studies of which 
appear promising. Three different ultrasound technologies have been used to 
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increase thrombolytic activity, including transcranial Doppler, transcranial color-
coded duplex, and low-frequency ultrasound. Essentially, these technologies use 
ultrasonic energy to augment the thrombolysis-induced return of blood flow 
through the neurovasculature affected by ischemic stroke (Tsivgoulis et al., 2010, 
Bor-Seng-Shu et al., 2012). 
A recent retrospective analysis compared the effect of sonothrombolysis plus 
intravenous thrombolysis to intravenous thrombolysis alone on the HMCAS-
positive patient group (Mattle et al., 2008, Eggers and Roessler, 2011). The 
authors reported a total of 72 patients who received intravenous thrombolysis 
alone and 28 who received sonothrombolysis with intravenous rtP A. Patients' 
ages and initial stroke severity were statistically similar. One hour after the 
intravenous rtP A bolus, recanalisation was seen more frequently in the 
sonothrombolysis group (partial 39% vs. 11 %; complete 25% vs. 14%, p = 0.003). 
After 3 months, a favorable outcome was more frequent in the sonothrombolysis 
group (mRS 0-1) 28% vs. 6% (p = 0.01); mRS 0-2 32% vs. 14%; and 12% vs. 
19% had died (n .s .) . 
Accordingly, ultrasound-assisted thrombolysis has been proposed as a viable 
addition to acute stroke management, particularly in the subgroup of patients with 
HMCAS who appear to be more resistant to recanalisation with standard therapy. 
The combination of ultrasound-assisted intra-arterial throrribolysis in the 
HMCAS-positive group has not yet been evaluated. 
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1.6 Summary 
The HMCAS is one of the earliest changes that can be detected on an NECT in 
acute ischaemic stroke affecting the middle cerebral territory. The sign is, for the 
most part subjectively reported and there is therefore the potential for 
disagreement on its presence or absence. It appears to be a representation of MCA 
occlusion and its disappearance is associated with recanalisation, as demonstrated 
by angiographic studies. The sign is highly specific for ischaemic stroke affecting 
the MCA. However, very few studies have assessed or formally evaluated the 
sensitivity and specificity outside the stroke population. 
The sign is associated with more severe strokes and probably with atrial 
fibrillation. Patients with the sign appear to have poorer outcomes than those who 
do not when acute treatment is not given, although no prospectiye intermediate to 
long term studies have looked at this. 
Those patients with the sign who qualify for intravenous thrombolysis appear to 
do better overall than those who are not acutely treated. However, a subgroup do 
not appear to benefit. This subgroup probably has larger clots underlying their 
strokes and the actual size of the HMCAS on the NECT may reflect this. 
In a small number of secondary analyses, patients with an HMCAS rece1vmg 
more aggressive thrombolytic technique, such as intra-arterial thrombolysis and 
ultrasound-assisted thrombolysis seem to perform better than those who receive 
standard intravenous therapy. However, these results are yet to be confirmed. 
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Although the HMCAS is well defined with a number of confirmed clinical 
associations, the literature on the subject overall is made up of predominantly 
retrospective analyses or small prospective studies. The small size of these studies 
and the lack of consistency amongst them in terms of controlled variables and 
outcome measures do provide a basis for important associations to be missed, and 
a propensity for false negative results. 
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1.7 Thesis aims 
As outlined above, there are a number of outstanding questions in relation to 
epidemiological, prognostic and reporting factors associated with the HMCAS. 
The purpose of this thesis is to help answer some of these questions by addressing 
the following aims: 
1.7.1 To calculate the prevalence, sensitivity and specificity of the HMCAS 
both within and outside the stroke population 
1.7 .2 To investigate the relationship between the HMCAS and other clinical 
data: e.g. Initial stroke severity, comorbidities and laboratory findings 
1.7 .3 To evaluate the intermediate to long term outcome of patients who present 
with an HMCAS who do not receive thrombolytic therapy 
1.7.4 To evaluate how reliably the HMCAS can be reported in standard clinical 
practice 
The experimental chapters in this thesis do not examine thrombolytic 
strategies and clinical research was conducted within a tertiary hospital 
that uses NECT as its primary imaging modality in the evaluation of acute 
stroke. 
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Chapter Two 
THE PREVALENCE, COMORBID ASSOCIATIONS AND PROGNOSTIC 
VALUE OF THE HMCAS: A PROSPECTIVE STUDY 
2.1 Introduction 
This study was set up to evaluate the prognostic significance of the HMCAS 
prospectively. In addition, we aimed to assess inter-observer variability in the 
detection of the sign and to look for any associations with clinical features in 
patients presenting with acute ischemic stroke. 
2.2 Materials and Methods 
2.2.1 Patient and CT scan recruitment 
Patients presenting to the Canberra Hospital with acute ischemic stroke or 
transient ischemic attack (TIA) were recruited prospectively between August , 
2009 , and December, 2010. Patients all underwent NECT scanning within 12 
hours of arrival. The control group was recruited within the same time frame as 
the active group and comprised patients admitted to Canberra Hospital for reasons 
other than stroke or TIA but still requiring NECT scans of the brain. 
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Patients were excluded from the study if: ( 1) the NECT scan was performed more 
than 12 hours after the onset of symptoms, (2) the NECT scan was of poor quality 
due to radiographic artifact (as determined by the reporting neuroradiologists), (3) 
the patient had significant pre-existing intracranial pathology (e.g. tumour or AV 
malformation), ( 4) the patient had undergone previous neurosurgery, or ( 5) the 
patient was less than 50 years old. 
All subjects gave informed consent. Both the ACT Health Human Research Ethics 
Committee (ETH. 11.08.1021) and the ANU Human Research Ethics Committee 
(2011/410) approved this study in May 2009. 
2.2.2 CT reporting 
All NECT scans were performed with multi-slice spiral CT (Toshiba Aquilion 16 
slice) with 1 mm contiguous axial slices from the occipital foramen to the skull 
vault with 1 mm reconstructions .. 
NECT scans of patients were de-identified and presented independently to two 
neuroradiologists who were blinded to the diagnosis. The neuroradiologists were 
asked to report on the presence or absence of ischemic stroke and to indicate 
whether or not there was an HMCAS using a standardised template designed 
specifically for this study. A HMCAS was reported as present if the MCA 
territory was deemed to be of sufficiently high attenuation relative to the 
contralateral side, the surrounding parenchyma and secondarily compared to the 
basilar aitery. If present, early parenchymal changes associated with cerebral 
infarction provided supportive information. They were also asked to note whether 
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the scan was inadequate for technical reasons. 
The scans were reviewed digitally using the Syngo V36 (2010) picture archiving 
and communication system (PACS). 
2.2.3 Clinical data collection and follow up 
Demographic, comorbid and laboratory data were collected for all stroke and TIA 
patients from the Canberra Hospital's computerised database. Information 
collected included a history of stroke, TIA, AF, congestive cardiac failure (CCF) , 
ischemic heart disease (IHD), hypertension, hypercholesterolemia, diabetes and/or 
smoking. Laboratory parameters recorded included haematocrit, haemoglobin, the 
international normalised ratio (INR), as well as the results of carotid Doppler. 
The Scandinavian Stroke Scale (SSS) was used to evaluate initial stroke sevelity 
within the emergency departme~t, as this was the standard clinical scale used at 
the Canberra Hospital at the time. The type 9f stroke was assessed and recorded 
according to the Oxfordshire Community Stroke Project classification system. 
A structured telephone interview was used to evaluate patient disability between 3 
and 6 months after symptom onset using the modified Rankin scale (mRS). 
2.2.4 Data analysis 
Inter-observer agreement between the two neuroradiologists was assessed using 
the Kappa statistic. For the purposes of further analysis an HMCAS was only 
considered to be present if both radiologists agreed. 
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Three analyses were performed in order to address the aims of this study. 
Analysis 1: This examined all strokes and TIA patients to determine the 
prevalence, sensitivity and specificity of the HMCAS as well as to investigate the 
presence of any comorbid associations with the sign. For this analysis, sensitivity 
was defined as the percentage of all strokes with an HMCAS (and, in this case, 
was therefore the same as prevalence), and specificity reflected the detection of an 
HMCAS in the control group. 
Analysis 2. This analysis was restricted to those patients who were experiencing 
their first-ever stroke in order to evaluate the relationships between the HMCAS 
and initial severity and outcome at 3 to 6 months. 
Analysis 3. This looked only at patients who had suffered a first-ever ischemic 
stroke in the MCA territory to allow comparison between patients with and 
without the HMCAS. 
T-tests, cross-tabulation, linear regression analysis and Fisher's exact test were 
used to evaluate associations between comorbid clinical features, SSS, mRS and 
the HMCAS. Associations were considered to be significant if p < 0 .05. 
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2.3 Results 
2.3.1 Baseline data 
In total, 117 patients with stroke or TIA (60 male, 57 female) and 65 control 
patients (28 male, 37 female) were recruited. The mean age of all stroke and TIA 
patients was 72 ± 2.6 years compared to 69 ± 3 .1 years in the control group (non-
significant) (Table 2.1). 
Table 2.1. Mean age of patients and controls and time to CT scan 
N Mean age Time to scan 
(years*) (hours*) 
All patients (Strokes and TIAs) 117 72 ± 2.6 4.6 ± 0.7 
Strokes 100 72 ± 2.6 4.6 ± 0.8 
Middle cerebral artery infarcts 61 72 ± 0.9 4.7 ± 1.0 
HMCAS +ve 15 77 ± 6.3 4.7 ± 1.1 
HMCAS -ve 46 71± 4.1 4.7 ± 1.1 
Other strokes 39 72 ± 4.2 4.9 ± 1.7 
HMCAS +ve 0 
HMCAS -ve 39 72 ± 4.2 4.9 ± 1.7 
TIAs 17 73 ± 7.0 4.3 ± 1.8 
Controls 65 69 ± 3.1 
*No statistically significant difference in means between all groups 
Of the 117 patients, 17 had TIAs, 61 had MCA territory infarcts, 20 had posterior 
circulation infarcts, 6 had infarcts in the anterior cerebral artery territory, 7 had 
posterior cerebral artery territory events and 6 were lacunar strokes. 
The mean time between stroke or TIA onset and imaging was 4 .6 ± 0 .7 hours. 
There was no significant difference in mean time from symptom onset to imaging 
across all groups of patients (Table 2 .1). 
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Comparison between the two neuroradiologists yielded a Kappa statistic of 
0.747, (Ci 95% 0 .590 - 0.945). 
Three patients within the stroke group were thrombolysed; all three were MCA 
strokes, one with an HMCAS and the other two without. Inclusion or exclusion of 
these patients did not alter the results significantly, so thrombolysed patients were 
included in the analyses below. 
2.3.2 Analysis 1 
In total, 15 patients were found to have an HMCAS on their emergency NECT. 
All of these suffered a stroke affecting their middle cerebral aitery. Thus, the 
prevalence of the HMCAS within the ischemic stroke population (N = 100, see 
table 1) was 15 % . The prevalence of the HMCAS within patients suffering from 
an infarct in the MCA territory was 25%. No controls were reported as having an 
HMCAS, i.e. the sign had a sensitivity of 15% and a specificity of 100%. 
Comorbid and laboratory data were then analysed as a function of HMCAS. In all, 
15 patients were HMCAS +ve, as above, and the remaining 102 patients 
(comprising, 46 HMCAS -ve MCA strokes, 39 other strokes and 17 TIAs) were 
HMCAS -ve. The only significant association that correlated positively with the 
presence of an HMCAS after performing linear regression analysis and applying 
Fisher's exact test was atrial fibrillation (Table 2 .2). 
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Table 2.2. Clinical features recorded and analysed for all ischemic stroke and 
TIA patients 
HMCAS+ve HMCAS-ve 
Demographic/ 
N= 15 N= 102 Pt 
Clinical Factor 
n (%) n (%) 
Sex (male) 11 (73) 53 (52) 0.507 
History of TIA 1 (7) 26 (25) 0.307 
History of Stroke 1(7) 25 (25) 0.305 
History of AF 8 (53) 19 (19) 0.042 
History of CCF 0 10 (10) 0.606 
History of IHD 2 (7) 19 (19) 1.000 
Hypercholesterolemia 11 (73) 80 (78) 1.000 
Hypertension 9 (60) 76 (75) 0.667 
Smoker 3 (20) 24 (24) 1.000 
Diabetes 2 (20) 16 (16) 1.000 
High Hematocrit 0 4 (4) 1.000 
High Hemoglobin 0 5 (5) 1.000 
Sub-therapeutic INR (patients 6 (75) 14 (73) 1.000 
with AF) 
Significant carotid stenosis 4 (27) 9 (9) - 0.099 
tFisher's exact test (two-tailed) P value compares the proportion with risk factor to the 
presence of an HMCAS 
2.3.3 Analysis 2 
After excluding 24 patients with previous stroke from the total of 100 patients 
with stroke (table 2.1), a total of 14 patients were HMCAS+ve and the remainder 
(N= 62) were HMCAS -ve. The initial stroke severity as determined by the SSS 
was significantly greater in patients with the HMCAS than in those without it (p = 
0.002) (Table 2.3). 
Similarly, the level of disability as assessed by mRS at 3 to 6 months in patients 
suffering their first-ever stroke was significantly greater in patients with the 
HMCAS than in those without it (p < 0.001) (Table 2.3). 
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Table 2.3. Initial deficit and disability associated with the presence of an HMCAS on 
NECT 
First-ever strokes First-ever strokes 
HMCAS -ve HMCAS+ve Significance+ 
N=62 N=14 p 
Initial Severity 
(mean SSS§) 46.2 ± 3.15 27 .9 ± 7.64 0.002 
Disability at 3-6 months 
(mean mRS) 2.0 ± 0.45 4.4 ± 1.1 < 0.001 
mRS II :S 2: n (%) 40 (65) 3 (21) < 0.001 
First-ever First-ever 
MCA strokes MCA strokes 
HMCAS -ve HMCAS+ve 
N=31 N= 14 
Initial Severity 
(mean SSS§) 43.6 ± 3.47 27.9 ± 7.64 0.006 
Disability at 3-6 months 
mRS II :S 2: n (%) 17 (55) 3 (21) 0.05 
+two tailed t-test (SSS) and Fisher's exact test 
§SSS: Scandinavian stroke score. Range: 2 in a maximally-impaired patient to 58 in a normal 
person 
llmRs: modified Rankin score. 0-2 (no - mild disability), 3-4 (significant disability) , 5-6 (high 
level disability or death). Dichotomized mRS :S 2 as favourable and mRS ;;:: 2 as poor outcome 
2.3.4 Analysis 3 
The prevalence of the HMCAS within patients suffering from an infarct in the 
MCA territory (N = 61) was 25%. Fifty-three percent of patients with an HMCAS 
and a first-ever MCA territory infarct had a diagnosis of AF compared to only 
19% in those without an HMCAS (p = 0 .042). It is worth noting that over 70% of 
patients who had a history of AF had a sub-therapeutic INR (less than 2) (Table 
2.2). 
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In this group, patients with an HMCAS had significantly more severe initial 
strokes and poorer outcomes at 3 to 6 months (Table 2.3). Specifically, at 3-6 
months only 3 (21 % ) of all patients presenting with an HMCAS on NECT had an 
mRS s 2 compared to 17 (55%) in all first ever MCA territory strokes (p = 0 .05) 
(Figure 2.1). 
First-ever 
MCA stroke 
HMCAS -ve 
First-ever 
MCA stroke 
HMCAS +ve 
0% 20% 40% 60% 80% 
mmRSO 
mlmRS1 
~mRS2 
fil'l mRS3 
GmRS4 
@3 mRS5 
BlmRS 6 
100% 
Figure 2.1. Modified Rankin scale outcomes of 31 first-ever MCA territory strokes without an 
HMCAS (upper bar) and 14 first-ever MCA territory strokes with an HMCAS (lower bar) 
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2.4 Discussion 
The results of this prospective observational study have shown that patients 
presenting with an HMCAS on their emergency NECT brain scan are highly 
likely to be suffering from ischemic stroke affecting the middle cerebral artery 
territory. These patients are more likely to exhibit more severe initial clinical 
deficit, to have atrial fibrillation, and to be severely disabled or dead within 3 to 6 
months following their stroke than stroke patients without the sign. 
There were no significant differences between groups in terms of baseline 
demographic data or the time between symptom onset and NECT scan. 
Agreement between radiologists on the presence of an HMCAS was good, but not 
excellent, according to the Kappa statistic. This level of discrepancy between 
specialist radiologists has been reported previously, and is not that surprising 
given the subjective nature of reporting (Tomsick et al., 1990; von Kummer et al., 
1994, Koo et al., 2000, Abul-Kasim et al., 2009, Eung et al., 2005). The 
possibility of disagreement raises concern in relation to the role of using the sign · 
to make time-critical clinical judgments, particularly because the scans will be 
read by .doctors with considerably less experience than the neuroradiologists who 
reported the scans in the present study. 
We found no false positives in this study. A small number have been described in 
the literature and it has been suggested that these may relate to inter-observer 
variability or, alternatively, to an elevated haematocrit and/or conditions that 
promote vascular calcification (Rauch et al., 1993). 
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After excluding all the patients who had previously suffered a stroke, those with 
an HMCAS had a more severe initial deficit. Restricting the analysis to new 
strokes within the MCA group alone did not alter this trend. Furthermore, our 
results clearly demonstrate that patients with an HMCAS have a poorer outcome 
between 3 and 6 months post stroke as assessed by the mRS. 
Atrial fibrillation is known to be associated with more severe ischemic stroke. 
However, we found that AF was significantly more common in patients with an 
HMCAS on NECT. This is consistent with the fact that the red blood cell content 
of the thrombus is likely to be higher in clots associated with atrial fibrillation 
(Minnerup and Kleinschnitz, 2011). 
The role of the HMCAS in contributing to the decision of whether or not to 
thrombolyse a patient with an acute ischemic stroke has been the subject of a 
number of studies, but the results remain inconclusive. Some authors have 
suggested a need for more effective, novel and potentially aggressive 
revascularisation techniques in these patients (Mattle et al., 2008, Abul-Kasim et 
al., 2010, Eggers and Roessler, 2011). 
Either way, it is important that the sign be detected accurately at the time of 
diagnosis and our finding of less than 100% agreement between experts casts 
doubt on the ability of non-experts to detect the presence or absence of the sign 
accurately. Some work has been done on this previously, suggesting that HMCAS 
sensitivity could be enhanced by changing the parameters of the CT scanning 
(Kim et al., 2008, Riedel et al., 2010b). However, this is unlikely to become 
standard practice when scanning patients in emergency departments and further 
work in this area is clearly necessary. 
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This study has a number of limitations. First, the numbers are small and, while the 
subjects were recruited prospectively, much of the data relating to clinical 
associations was assessed retrospectively from patient charts. Second, stroke 
severity was assessed using the Scandinavian Stroke Scale rather than the more 
commonly-used NIH stroke scale. This was due to the fact that the SSS was the 
standard clinical tool used in the department at the time of the study. Finally, the 
3-6 month follow-up period is somewhat broad but was used for practical reasons. 
Although we did not control for this amongst the patients, we expected the 
outcome beyond 3 months and within 6 months to be consistent. While 
acknowledging all these possible limitations, we do not believe they would have 
had a significant impact on the conclusions. 
It is also worth mentioning that we acknowledge that emerging CT guided 
techniques for the evaluation of acute stroke are being util!sed in some major 
centres. CT-perfusion is one such modality, and this may generally supercede the 
use of NECT in time, however this is certainly not the case yet , particularly in 
peripheral centres (Hoeffner et al., 2004, Campbell et al., 2011, Campbell et al., 
2012). 
In conclusion, we have addressed this study's three aims and demonstrated 
prospectively that the untreated outcome at 3 to 6 months is significantly worse in 
patients with the HMCAS than those without it. Secondly, we have demonstrated 
that the level of agreement between expert neuro-radiologists when looking at 
standard clinical scans is only 0.747. Third, we have confirmed an association 
between the presence of the sign with both atrial fibrillation and a more severe 
stroke. Because it has been suggested that the sign may be useful in determining 
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the role of thrombolysis in the acute setting, more work is needed, particularly 
with a view to investigating the reliability of detection of the sign and so reducing 
the possibility of inter-observer variability. 
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Chapter Three 
THE RELIABILITY OF HMCAS REPORTING IN CLINICAL PRACTICE 
3.1 Introduction 
As outlined in chapter one, radiologists generally report the HMCAS usmg 
subjective observational criteria. 'Gold standards' have been published but these 
are rarely used in clinical practice (Abul-Kasim et al., 2009). The individuals 
reporting the presence/absence of the sign early-on in patient management (when 
it may make a difference to acute treatment decisions) tend to be junior staff or 
emergency department physicians, not senior clinicians or experienced 
neuroradiologists (who generally report the scans hours to days later). This means 
that there is considerable scope for error in diagnosis and, therefore, management. 
Since the HMCAS is a useful and important sign and may alter time-critical 
decisions within an emergency setting it is important to know if less experienced 
clinicians can report the presence of the sign with a degree of accuracy 
comparable to that of experts. 
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This study was accordingly set up to evaluate the accuracy in the reporting of the 
HMCAS across doctors practising within a tertiary medical facility with varying 
levels of experience. More specifically, the study aimed to assess whether non-
experts could, after a brief tutorial, report the presence or absence of the sign as 
well as experts. This research further aimed to evaluate how consistently experts 
reported the presence of the sign and to correlate subjective reporting with the 
radiological density of the MCAs as measured in HU. 
3.2 Materials and Methods 
This study was approved by the ACT Health Human Research Ethics Committee 
(ETHLR.11.202) and the ANU Human Research Ethics Committee (211/567). 
3.2.1 Subject selection 
Forty subjects were recruited into four separate categories (10 in each) based on 
clinical experience. All subjects were qualified medical doctors and gave 
informed consent. The categories were as follows: 
Category 1 - Interns and Resident Medical Officers 
Category 2 - Basic Physician Trainee Registrars and Senior Registrars in medical 
and surgical specialities, excluding Neurology and Radiology. 
Category 3 - Emergency specialists and senior registrars in Neurology and 
Radiology 
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Category 4 - Consultant Neurologists and Radiologists 
3.2.2 Scan selection 
Scans suitable for this study were selected from the database of 187 NECT brain 
scans from the previous experiment using a pre-designed quantitative matrix 
based on standard background viewing values for the scans; i.e. a level (centre) of 
40 HU and a window of 90 HU. The matrix (displayed in Table 3.1) was designed 
to select scans that would represent a broad range of MCA radiological densities. 
In total, 19 scans were selected to populate this grid. The density of the MCAs 
across these scans ranged from sub-normal, through normal, to hyperdense and 
the scans covered a range of relative densities between left and right MCAs. 
Table 3.1. Nineteen NECT brain scans demonstrating a spectrum of 
absolute and relative absolute densities 
Maximum (HU) 
50-55 
47-49 
44-46 
41-43 
38-40 
35-37 
::sl.05 
MCA Ratio 
1.1-1.2 ::!::l.25 
RED: Radiological predictor of HMCAS or "gold standard" as previously reported (6 points) 
ORANGE: Relatively high combination of absolute and relative densities however did not 
achieve the red cut-off (5 points): 
Very high absolute density of one MCA plus moderate relative density MCAs; 47 HU :5 
MCAmax :5 55 HU plus 1.1 HU :5 MCAret :5 1.2 HU 
OR 
Moderate absolute density of one MCA plus high relative density; 41 :5 MCAmax :5 43 HU 
plus MCAret ~ 1.25 
Within the moderate range of normal MCA absolute and relative densities (4 
points): 
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41 HU :5 MCAmax :5 46 HU plus 1.1 HU :5 MCArei :5 1.2 HU 
GREEN: High absolute MCA density , however low relative density when compared to scans 
in the yellow category (3 points): 
47 HU :5 MCAmax :5 55 HU plus MCArei :5 1.05 HU 
BLUE: Relatively low combination of absolute and relative densities (2 points): 
Moderate absolute density of one MCA plus low relative density MCAs; 44 HU :5 
MCAmax :5 46 plus MCArei :5 1.05 HU 
OR 
Low absolute density of one MCA plus moderate relative density MCAs; 38 HU :5 
MCAmax :5 40 plus 1.1 HU :5 MCArei :5 1.2 HU 
WHITE: Lowest combination of absolute and relative density MCAs (1 point): 
Low - moderate absolute density of one MCA plus low relative density MCAs; 35 HU :5 
MCAmax :5 43 HU plus MCArei :5 1.05 HU 
OR 
Very low absolute density of one MCA plus moderate relative density MCAs; 35 HU :5 
MCAmax :5 37 plus 1.1 HU :5 MCAret :5 1.2 HU 
The densities were calculated from oval RO Is (0 .03 - 9 .07 cm2) and were 
measured in HU. These values were divided into six groups according to how 
closely they met the definition of HMCAS as outlined in chapter 1, section 1.2. 
For example, scans which fully satisfied the criteria: MCAattenuation ~ 46 HU and 
MCAattenuation ratio > 1.2 using oval RO Is (the "red" group) represented he "gold 
standard". Other groups ( orange, yellow, green, blue and white) were filled by 
scans that failed to meet the criteria by progressively greater amounts (see table 
3 .1). Scans were assigned a point score (1-6) based on the combination of 
absolute and relative MCA densities measured. For example, a scans that had a 
high absolute MCA density (MCAmax) but low relative MCA densities (MCArei) 
were assigned 3 points, whereas scans that had a low-moderate MCAmax and a low 
MCArei were assigned 1 point. 
51 
Scans had to have clearly discernable MCAs and not be affected by radiological 
artefact as determined by an expert radiologist. 
3.2.3 Experimental template development 
The 19 NECT brain scans were de-identified using a built-in function within the 
P ACS program to clear all information relating to patient identity. The right and 
left MCAs were then identified using the scroll function and screenshots were 
taken of consecutive Imm slices containing either the right or left MCA and at 
least one slice caudal and rostral to this region. The number of slices required in 
order to demonstrate both left and right MCAs adequately ranged in different 
scans from 4 to 10. The resolution of the images was preserved in each 
screenshot. 
The de-identified Imm axial slices were copied into a Microsoft PowerPoint 
document and layered in such as way as to mimic the exact format within the 
standard hospital PACS without any degradation in quality. Five introductory 
slides as displayed in figure 3 .1 were added to provide the information required 
for subjects to use the template. Hyperlinks were programmed into the 
PowerPoint presentation to allow subjects to report the scans in a specific 
allocated randomised order. 
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2. You are to decide on whether you think you see an HMCAS on the scans in this 
study. 
KEY TIPS - READ CAREFULLY 
- Look at the absolute brightness of each MCA and compare it to the other 
side as well as the surrounding parenchyma. 
- It should be significantly brighter than the parenchyma, and It is NOT an 
HMCAS if both the left and ri ht side are e uall bri ht. 
- There are between 5 and 12 slices for each patient's CT scan to allow you 
to scroll back and forth com arin the left and ri ht side. 
3. ONE RULE: You may scroll back and forth as many times as you like between the 
slices within one scan (CT 1 -1, CT 1 -2 etc .. ) BUT YOU MUST NOT scroll between 
different patient's scans (CT 1, CT 2 etc .. ). Each scan must be reported 
independently . 
At the end of each CT, click "Next CT" and this will jump you back to the scan 
selection page. YOU MUST REPORT THEM IN THE ORDER SUPPLIED TO YOU. 
THANK YOU AND HAVE FUN! ... 
Figure 3.1. Introductory slides for the reliability of HMCAS reporting in clinical 
practice experimental template 
The PowerPoint document was loaded onto multiple separate external storage 
devices and kept secure prior to distribution. 
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3.2.4 Data collection 
Each of the 40 subjects was given a reporting sheet along with an order in which 
to report the scans. The reporting sheet is shown in figure 3 .2. The order of 
reporting the 19 scans was randomised to minimise bias due to learning or fatigue. 
A program that took into account the six groups of differing radiological density 
generated the different reporting orders. 
Subjects viewed the PowerPoint presentation on the standard display monitors 
available at The Canberra Hospital (Hewlett Packard HP Compaq LA2405wg) 
and were simply asked to indicate if they could see an HMCAS as per the 
instructions and, if so, on which side. 
The completed reporting sheets were then collated and the data were stored on a 
security-protected excel database. 
[he HMCAS reporting study 
Do you think there is an HMCAS present? 
You must report the scans In ttte !ollow!ng order 
UJ,lng the CT selection screen, truink: you. 
CT I HMCAS ptesent? I .Left {t} or Right (R) 
(ilck box tf YES) 
17 
13 
16 
12 
15 
19 
18 
11 
14 
10 
ONCE COMPLETE PL.EASE CONTACT ME.on 04053a905:l OR 
Viti EMA it. at pa!rli:k .. aoftad@msn.mm1, S-0-THAT i CAN 
COLLECT TME use A.NO nus FORM, THANK YOU, 
102: 
Figure 3.2. Reporting sheet completed by subjects in the 
reliability of HMCAS reporting in clinical practice experiment 
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3.2.5 Data analysis 
The three scans in the gold standard (red) category were selected because they met 
the definition of HMCAS in the literature (MCAattenuation ~ 46 HU and MCAattenuation 
ratio> 1.2 using oval ROis) and were therefore considered to be "true positives". 
The 16 remaining scans were considered to be "true negative". All subjects' 
answers were initially analysed to generate a mean "correctly-reported" result. 
Analysis of variance (ANOV A) was performed to assess the difference in results 
across the four levels of experience using a 4 x 1 factorial model. Post-hoc 
analyses were then performed using the Dunnett t-test (2-sided) to make pairwise 
comparisons between groups. 
The sensitivity, specificity, positive predictive value (PPV) and negative 
predictive value (NPV) were then calculated for each of the four groups. Finally, 
the false positive rate was determined as a function of group for each of the five 
"true negative" categories. This was performed in order to determine whether 
there was an interaction between the degree to which the scans approximated a 
"true positive" and level of experience. 
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3.3 Results 
Table 3 .2 lists the overall percentage correct score of each subject. A single 
subject from group 4 reported issues with utilising the PowerPoint template and 
his data were therefore discarded. As can be seen, the degree of the range of 
results decreased and the overall mean percentage correct scores increased within 
reporting categories in accordance with level of experience (scores 57 .89 - 94.74 
in group 1, 63.16 - 89.47 in group 2, 63.16 - 94.74 in group 3 and 84.21 - 100 in 
group 4). It is interesting to note that the only score of 100% correct was obtained 
by the most senior expert radiologist ( 403). 
Table 3.2. Individual subject results 
Group Correct Group Correct Group Correct Group Correct 
1 (%) 2 (%) 3 (%) 4 (%) 
101 68.4 201 89.5 301 94.7 401 84.2 
102 89.5 202 84.2 302 79.0 402 89.5 
103 68.4 203 84.2 303 79.0 - 403* 100 .0 
104 89.5 204 73.7 304 79.0 404 94.7 
105 73.7 205 68.4 305 79.0 405 79.0 
106 68.4 206 73.7 306 94.7 406 94.7 
107 94.7 207 73.7 307 94.7 407 94.7 
108 79.0 208 63.2 308 89.5 408 84.2 
109 57.9 209 73.7 309 84.2 409 89.5 
110 79.0 210 79.0 310 63.2 410 t 
* Most senior neuroradiologist 
t Omitted from all analyses 
Analysis of variance revealed a significant effect of group on mean percentage 
correct [F(3,35) = 4.54, p < 0.01]. Post-hoc Dunnett t-tests revealed that there was 
a significant difference between groups 1 and 4 and groups 2 and 4 (p < 0 .05) but 
not between groups 3 and 4 (Table 3 .3, figure 3 .3). 
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Table 3.3 Mean percentage correctly reported scans(± SE), by experience Group 
Experience Group 1 2 3 4 
76.8 ± 3.69 76.3 ± 2.51 83.7±3.18 90.l ± 2.23 
100 
95 ','!'="""'"'"''=h»==»<·>»>>'~'>»X<»>m=&>0,,,.,.,.,.,.,,,.,,.,._,,,,«·~»;,c,,,.,.,,,,,,,w,»-,.,.,,,,.,c«·»»===.c·m>>c·>'<·C<·>C0i,'tCx=0,,;,c,w~«<<>=>»ms»;c=,@,,,.,c,o;c,,ws,,»=,"·""'==·,·'·'"'''""""""'"-"°""M»=>e·,·'·'·'>'· 
90 4·x«,,,,.,.,,,,,,,."o,,,,.,.,.,.,.,,,,.,,,,,.,.,,~»»>e 
Mean 
,correct 85 ,,t,.,.,,,.,.,,.,,,,,,,;;,,,.,.,,,,.,.,.,.,.,,.,.,.,,.,,.,.,,"'., 
(%) 
:&O x4,,,-m,,,,,,,,=,,,-,m»m» 
75 
70 
1 2 
Experience Group 
3 
Figure 3.3: Comparison of mean percentage correct across_ each experience 
group versus group 4 (dark grey - highest level of experience): asterisk 
represents statistical significance (p < 0.05). 
The sensitivity (the proportion of true positives that were correctly identified), the 
specificity (the proportion of true negatives that were correctly identified), the 
positive predictive value (the proportion of positive reports that were true 
positives) and the negative predictive value (the proportion of negative reports 
that were true negatives) are shown in table 3 .4 for each of the four groups. 
As can be seen, group 4 performed best on all measures but there was gradual 
improvement across the groups with increasing level of experience. Having said 
this, the PPV results were relatively low in all groups: even in the expert group 
(group 4), there was only a 65% chance that a scan reported as positive met the 
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requirements of a true positive scan as stated in the literature. However, the NPV 
was high in all four groups, meaning that if a doctor with any level of experience 
reported a scan as negative for an HMCAS it was likely to be a true negative. 
As in the methods section, the 16 "true negative" scans were classified according 
to how closely the parameters met the "gold standard" of HMCAS referred to in 
the literature, with white being the furthest away from true positive and orange 
being the closest. The false positive rates for each of the five categories are shown 
in figure 3 .4 as a function of group. 
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Figure 3.4: Proportion of false positive HMCAS reports in different categories of scan 
as a function of level of experience (group) 
Table 3.4 Sensitivity , specificity , false negative and false positive rate for the four 
experience groups 
Group Sensitivity (% )t Specificity (% )t PPV (%)t NPV (%)t 
1 63 [11 , 98] 79 [52, 94] 36 [6, 80] 92 [62, 99] 
2 67 [13 , 981 78 [5, 931 36 [7, 79] 93 [63 , 100] 
3 70 [14, 99] 86 r59 , 971 49 r9, 891 94[66, 100] 
4 81 [20, 100] 92 [65 , 99] 65 [15 , 97] 96 [70, 100] 
t 95% Confidence Interval 
Group 4 had the lowest false-positive rate for each category , but there was no 
obvious interaction between category and group. Unfortunately, the numbers in 
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each group were too low to permit an analysis of variance to be performed on 
these data. 
Supplementary data: 
Table 3.5 Proportion of subjects in each 
group who positively reported an HMCAS 
on each of the 19 NECT scans organised by 
colour category 
Doctor level of experience 
4 0.50 0.50 0.30 0.22 
5 0.50 0.50 0.30 0.22 
6 0.10 0.10 0.20 0.22 
7 I 0.20 · 0.20 0.30 0.11 
8 0.10 0.00 0.00 0.00 
9 0.30 0.50 0.10 0.11 
10 0.40 0.20 0.20 0.00 
11 0.10 0:00 · 0.10 0.11 
12 0.40 0.60 0.30 0.11 
16 0.00 0.00 0.00 0.00 
17 0.00 0.30 0.10 0.00 
18 0.30 0.20 0.10 0.11 
19 0.30 0.10 0.20 0.00 
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3.4 Discussion 
The purpose of this experiment was to assess whether or not experts should be 
involved in the identification of an HMCAS or if less experienced staff could 
make an accurate call. If less experienced clinicians were able to report the 
presence or absence of an HMCAS with a similar level of accuracy to experts this 
would enhance patient management in the acute setting. 
The raw data showed that there was a large degree of variability when reporting 
the presence or absence of an HMCAS. The variability was most pronounced 
amongst inexperienced reporters and was lower in the expert group (group 4). The 
mean number of correctly reported scans increased with experience and the 
difference in scores between groups was statistically significant. 
More experienced subjects were able to identify both true positives and true 
negatives more accurately than juniors. In the case of experienced subjects, there 
were very few false positives (specificity 92% ). The sensitivity was less good, 
however (81 % ) . In this particular study this may have been related to one 
particular scan (number 2) which met the radiological criteria for an HMCAS but 
which was reported as positive far less often than the other two scans in this 
category. Why this should have been is unclear. As there were only three true 
positives in the entire study, the true sensitivity may have been under-estimated. 
Overall, a negative report meant that the presence of a true HMCAS was highly 
unlikely as NPV s were high in all groups, but a positive report did not necessarily 
mean there was a true HMCAS present. The fact that the NPV was high is useful 
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in the emergency setting as a negative report would mean that a patient would be 
(correctly) unlikely to receive some of the alternate treatment measures being 
suggested for HMCAS-positive patients presenting with acute ischaemic stroke 
(Agarwal et al., 2004, Mattle et al., 2008, Eggers and Roessler, 2011). The fact 
that even among experts the PPV was only 65% was disappointing but it was still 
markedly better than the PPV of the inexperienced subjects. As above, there were 
only three true positive scans in the study and it is possible that the small number 
may have led to an underestimate of the true PPV. 
As expected, the false positive rate was highest in scans within the orange 
category. There was no particular interaction between group and false positive 
rate in the various colour categories except that groups 1 and 2 were more likely 
to report false positive than groups 3 and 4. In other words, less experienced 
reporters tended to over-report the sign when compared to more experienced 
reporters. 
Equivocal scans within the orange category would be most likely to benefit from a 
second opinion or the application of objective criteria using imaging software. 
The application of objective criteria by reporters generally assists management by 
improving accuracy and consistency. However, the use of software to measure 
radiological criteria in a busy emergency department is relatively impractical and 
is unlikely to be taken up in routine clinical practice. 
Interestingly, many of the less experienced subjects were not aware of the 
existence of the HMCAS prior to their involvement in this study. This study 
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demonstrates that despite limited education junior staff were able to identify an 
HMCAS, but not confidently comment on its absence. 
This experiment was limited in that scans were viewed without relevant clinical 
information. It has previously been shown that when clinical information is 
provided, experts improve their level of agreement and accuracy (von Kummer et 
al., 1996). If clinicians had been provided with clinical data to accompany the 
scans they were reporting, the level of accuracy and consistency amongst and 
within groups would almost certainly have been better, particularly within the 
expert group. However, this study was specifically designed to look at the ability 
to report on the presence or absence of the HMCAS on NECT scans in isolation. 
The allocation of doctors into four experience groups was empirical, based on the 
expected degree of day-to-day exposure to NECT brain scari reviewing coupled 
with the level of seniority and experience. There would, of course, have been 
intrinsic variability within each group. However, the fact that the results 
demonstrated a steady trend to greater accuracy with increasing level of 
experience suggests that this empirical allocation was reasonable. It is worth 
noting that clinical experience and the trend towards the diagnostic accuracy of 
stroke syndromes is not only present when interpreting CT data, but also on 
bedside assessment (Hand et al., 2006). 
In conclusion, the reported absence of an HMCAS by a clinician of any level of 
experience is highly likely to imply a true negative. The accurate detection of the 
presence of an HMCAS, on the other hand, increases markedly with experience. 
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This suggests that the reporting of NECT scans in the assessment of acute stroke 
is best undertaken by more experienced clinicians, although better education of 
junior staff in the future could change this. 
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Chapter Four 
CONCLUSIONS AND RECOMMENDATIONS 
4.1 Overview of literature review (chapter 1) 
The HMCAS is a radiological sign that is becoming increasingly important in the 
acute management of acute ischaemic stroke. It appears t~ correlate with the 
presence of a clot in the middle cerebral artery (MCA) and its disappearance 
corresponds to recanalisation. 
The HMCAS has been defined as an appearance of increased attenuation or 
increased radiological density over and above that which would be expected of the 
normal proximal MCA on NECT. This definition is, however, subjective and 
radiological criteria have been defined to reduce the subjective nature of 
reporting. Even so, there is significant variability in the reporting of an HMCAS , 
particularly in the emergency clinical setting. Quantitative methods are rarely used 
in clinical practice. 
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The sign is most commonly seen within the first few hours after ischaemic stroke 
and appears to be present in approximately one quarter to one third of all NECT 
brain scans of patients suffering an ischaemic stroke within the MCA territory. It 
is highly specific for an MCA stroke but it has a low sensitivity so its absence 
does not exclude stroke. It is associated with the presence of AF, a more severe 
initial neurological deficit and a poorer short term outcome. Up until the 
experimental work contained in this thesis, no intermediate to long term 
prospective studies have been carried out to evaluate patient ouctcome in the 
absence of thrombolytic therapy. 
Patients who present with an HMCAS and receive intravenous thrombolysis 
appear to benefit less as a group than those who do not present with the sign but 
they benefit more than those who do not receive intravenous thrombolysis at all. 
This may be a function of the underlying thrombus, which has been proven to 
correlate with the length of the HMCAS in NECT. 
There appears to be no increase in the haemorrhagic complication rate of 
thrombolysis in patients with the HMCAS. 
Intra-arterial thrombolysis has not yet been proven to be more advantageous than 
intravenous thrombolysis in the ischaemic stroke population as a whole but it may 
provide additional benefit to carefully-selected patients who present with an 
HMCAS. Similarly, ultrasound-assisted thrombolysis has been proposed in the 
subgroup of patients with HMCAS who appear to be more resistant to 
recanalisation with standard therapy but this has not yet been evaluated. 
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4.2 Overview of experimental results and limitations (Chapters 
2 and 3) 
The background prevalence of the HMCAS was low but the sign was highly 
specific, (100%), for ischaemic stroke affecting the MCA territory. The sensitivity 
of the sign was low (15%). The presence of an HMCAS was associated with a 
more severe initial deficit on the SSS and the only comorbid characteristic that 
correlated with the presence of an HMCAS was AF with a sub-therapeutic INR. 
The untreated intermediate-long term prognosis of patients who presented with an 
HMCAS was very poor with the majority of patients being highly dependent or 
dead at 3-6 months (mRS ~ 4). 
The reliability of reporting the HMCAS amongst experts was very good.' 
However, inter-observer agreement remained an issue under controlled 
conditions. The reported absence of an HMCAS by a clinician of any level of 
experience was highly likely to imply a true negative. The accurate detection of 
the presence of an HMCAS, on the other hand, increased markedly with 
expenence. 
There were some significant limitations with the above experimental work that 
require acknowledgement. Firstly, the number of patients in the study described in 
chapter one was relatively small. Secondly, while the subjects were recruited 
prospectively, much of the data relating to clinical associations were assessed 
retrospectively from patient charts. Also, stroke severity was assessed using the 
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Scandinavian Stroke Scale rather than the more commonly-used NIH stroke scale. 
[This was due to the fact that the SSS was the standard clinical tool used in the 
department at the time of the study.] It might have been useful to perform 
angiography on patients recruited to the study but this was not clinically or 
practically feasible. Finally, the length of the HMCAS on NECT scans was not 
measured. This may have assisted in corroborating previously reported data on the 
size of the HMCAS and prognostic implications. 
The study described in chapter 3 took place in an environment away from the 
emergency department. This was done with a view to eliminating confounding 
variables and thus attempting to assess clinicians' true ability to report HMCAS. 
This experiment was therefore somewhat artificial in that scans were viewed 
without access to relevant clinical information. It has previously been shown that 
when clinical information is provided, experts improve their level of agreement 
and accuracy. 
While acknowledging all these limitations, it is considered unlikely that they 
would have had a significant impact on the conclusions drawn from the study. 
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4.3 Implications for current clinical practice 
The results of the literature review and these experiments make it possible to 
provide recommendations to institutions that predominantly rely on NECT as their 
primary tool for investigation of acute ischaemic stroke. 
First, all clinicians who are responsible for the acute care of ischaemic stroke 
patients should be made aware of the existence of the HMCAS and invited to look 
for it specifically when assessing the initial NECTs. Once educated in this way, if 
the opinion of a clinician of any experience level reviewing the scan is that there 
is no HMCAS present, then it highly likely to be truly absent. 
If, however, the clinician believes an HMCAS is present they should consider 
asking for the scan to be reviewed by someone of greater experience (e.g. a 
consultant radiologist). Quantitative measurement of the HU density of the 
MCAs may be useful. On the basis of studies performed elsewhere, it would also 
be useful to measure the length of the hyperdensity and categorise it as either: 
1. Short length HMCAS (< 1cm) 
11. Medium length HMCAS (1-2 cm) 
111. Long length HMCAS (> 2cm) 
Once the presence of an HMCAS has been confirmed in the appropriate clinical 
setting the implications for treatment and the prognostic implications can be 
discussed with the patient or carer to generate an informed treatment plan. If the 
patient with an HMCAS is not eligible for thrombolytic therapy then a discussion 
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should take place informing the relevant parties that the prognosis in both the 
short and long term is likely to be very poor. 
If a patient is eligible for thrombolysis then, in addition to discussing the relative 
risks and benefits of thrombolytic therapy, relevant parties should also be 
informed of the increased risk of failure in HMCAS-positive patients ~ especially 
when the clot is greater than 2cm in length on high-resolution NECT. The chance 
of overall benefit to patients in this particular subgroup is about the same, or 
possibly less , than the risk of thrombolysis-associated haemorrhage. 
Patients presenting with ischaemic stroke and HMCAS on NECT are very likely 
to have underlying atrial fibrillation and therefore should be thoroughly 
investigated and treated for this condition where appropriate. 
Wherever possible, HMCAS-positive stroke patients should be enrolled in clinical 
trials assessing the alternative interventional strategies as outlined in Chapter 1. 
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4.4 Suggestions for future research 
The significant advances in imaging technology are constantly improving the 
quality of information that clinicians have access to in the setting of acute stroke. 
More advanced methods may supersede the use of the plain NECT in the near 
future. However, for many hospitals the NECT remains the primary initial 
investigation for acute stroke and a thorough understanding of its use is therefore 
required. 
The natural history and clinical characteristics of ischaemic stroke patients 
presenting with an HMCAS have now been elucidated. Given that its presence has 
a significant impact on prognosis and treatment, future research should focus on 
improving the accurate detection of the HMCAS by clinicians and clarifying 
which therapeutic interventions confer a morbidity and mortality benefit when it 
is present. 
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